Solid Tumor clinical trials at UCLA
136 in progress, 74 open to eligible people
KVA12123 Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)
open to eligible people ages 18 years and up
The goal of this clinical trial is to test the safety and efficacy of KVA12123 alone or combined with pembrolizumab in patients with advanced solid tumors. The main questions this study aims to answer are: 1. What is the safety of KVA12123 when…
Santa Monica, California and other locations
AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
open to eligible people ages 18 years and up
The purpose of this study is to evaluate the safety and tolerability of: - casdatifan when taken alone in participants with advanced solid tumor malignancies and clear cell renal cell carcinoma (ccRCC) during the dose escalation stage; and -…
Santa Monica, California and other locations
CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
open to eligible people ages 18 years and up
The goal of this clinical trial is to test CPO301, a type of drug called an antibody drug conjugate in adult patients with advanced or metastatic solid tumors. The main questions it aims to answer are: - To assess the safety and tolerability of…
Santa Monica, California and other locations
First in Human Study of TORL-4-500 in Patients with Advanced Cancer
open to eligible people ages 18 years and up
This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-4-500 in patients with advanced cancer. For Part 1, any advanced or metastatic solid tumor malignancy will be evaluated including, for …
Los Angeles, California and other locations
IAG933 in Patients With Advanced Mesothelioma and Other Solid Tumors
open to eligible people ages 18-120
The purpose of this study is to characterize the safety and tolerability of IAG933 in patients with mesothelioma, NF2/LATS1/LATS2 mutated tumors and tumors with functional YAP/TAZ fusions and to identify the maximum tolerated dose and/or recommended …
Los Angeles, California and other locations
AZD8205 Given Alone or in Combination With Anticancer Drugs, in Participants With Advanced or Metastatic Solid Malignancies
open to eligible people ages 18 years and up
This research study is studying a new compound, AZD8205, as a possible treatment for advanced or metastatic solid tumours alone or in combination with anti-cancer agents
Santa Monica, California and other locations
Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
open to eligible people ages 18 years and up
KB707-01 is a Phase 1/2, open-label, multicenter, dose escalation and expansion study. The study will evaluate the safety and tolerability of KB707 in adults with locally advanced or metastatic solid tumors who have progressed on standard of care…
Los Angeles, California and other locations
AB248 Alone or in Combination with Pembrolizumab in Adult Patients with Solid Tumors
open to eligible people ages 18 years and up
This is a phase I, First-in-Human (FIH), open-label study to evaluate the safety, tolerability, pharmacokinetic (PK) profile, and preliminary efficacy of AB248 as monotherapy OR in combination with pembrolizumab in adult participants with locally…
Los Angeles, California and other locations
ADRX-0706 in Select Advanced Solid Tumors
open to eligible people ages 18 years and up
The primary purpose of this study is to assess the safety, tolerability, and pharmacokinetics, and to identify the optimal dose of ADRX-0706 in patients with select advanced solid tumors.
Los Angeles, California and other locations
APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors
open to eligible people ages 12 years and up
This study aims to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of APG-115, an MDM2 inhibitor, either alone or in combination with pembrolizumab, a programmed cell death protein-1 (PD-1) inhibitor, in patients with…
Los Angeles, California and other locations
ASP3082 in Adults With Advanced Solid Tumors
open to eligible people ages 18 years and up
This is an open-label study. This means that people in this study and clinic staff will know that they will receive ASP3082. The study aims to check how safe and well-tolerated ASP3082 is for people with advanced solid tumors that have a specific…
Santa Monica, California and other locations
DB-1310 in Advanced/Metastatic Solid Tumors
open to eligible people ages 18 years and up
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1310 in subjects with advanced solid tumors.
Santa Monica, California and other locations
DB-1311 in Advanced/Metastatic Solid Tumors
open to eligible people ages 18 years and up
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1311 in subjects with advanced solid tumors.
Los Angeles, California and other locations
Disitamab Vedotin Alone or With Other Anticancer Drugs in Solid Tumors
open to eligible people ages 18 years and up
This clinical trial is studying solid tumor cancers. A solid tumor is one that starts in part of your body like your lungs or liver instead of your blood. Once they've grown bigger in one spot or spread to other parts of the body, they're harder to…
Santa Monica, California and other locations
LOXO-435 in Participants With Cancer With a Change in a Gene Called FGFR3
open to eligible people ages 18 years and up
The main purpose of this study is to learn more about the safety, side effects, and effectiveness of LOXO-435. LOXO-435 may be used to treat cancer of the cells that line the urinary system and other solid tumor cancers that have a change in a…
Santa Monica, California and other locations
NT-112 in HLA-C*08:02-Positive Adult Subjects With Unresectable, Advanced, and/ or Metastatic Solid Tumors Positive for the KRAS G12D Mutation
open to all eligible people
Phase I Study of NT-112, an autologous T-cell therapy product genetically engineered to express an HLA-C*08:02-restricted T cell receptor (TCR), targeting KRAS G12D mutant solid tumors.
Los Angeles, California and other locations
NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
open to eligible people ages 18 years and up
Phase I Study of NT-175, an autologous T cell therapy product genetically engineered to express an HLA-A*02:01-restricted T cell receptor (TCR), targeting TP53 R175H mutant solid tumors.
Los Angeles, California and other locations
PF-08046052/SGN-EGFRd2 in Advanced Solid Tumors
open to eligible people ages 18 years and up
This study will test the safety of a drug called PF-08046052/SGN-EGFRd2 in participants with advanced solid tumors. It will also study the side effects of this drug. A side effect is anything a drug does to the body besides treating the disease.…
Santa Monica, California and other locations
Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
open to eligible people ages up to 25 years
Phase 1 will evaluate the safety and tolerability at different dose levels of repotrectinib in pediatric and young adult subjects with advanced or metastatic malignancies harboring anaplastic lymphoma kinase (ALK), receptor tyrosine kinase encoded…
Los Angeles, California and other locations
SGN-B6A in Advanced Solid Tumors
open to eligible people ages 18 years and up
This trial will look at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe for people who have solid tumors. It will study sigvotatug vedotin to find out what its…
Los Alamitos, California and other locations
SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
open to eligible people ages 18 years and up
Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of SNS-101, a novel anti VISTA IgG1 monoclonal antibody as monotherapy or in combination with cemiplimab in patients with advanced solid tumors.
Los Angeles, California and other locations
XMT-1660 in Participants With Solid Tumors
open to eligible people ages 18 years and up
A Study of XMT-1660 in Solid Tumors
Santa Monica, California and other locations
XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2
open to eligible people ages 18 years and up
A Study of XMT-2056 in advanced/recurrent solid tumors that express HER2.
Los Angeles, California and other locations
INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
open to eligible people ages 18 years and up
This study is conducted to determine the safety and tolerability of INCB161734 as a single agent or in combination with other anticancer therapies.
Santa Monica, California and other locations
KIN-2787 in Participants with BRAF And/or NRAS Mutation Positive Solid Tumors
open to eligible people ages 18 years and up
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of KIN-2787 in adults with BRAF/NRAS-mutated advanced or metastatic solid tumors.
Los Angeles, California and other locations
NST-628 Oral Tablets in Subjects with Solid Tumors
open to eligible people ages 18 years and up
This is a two-part Phase 1, open label, multi-center, single arm, non-randomized, multiple dose, safety, pharmacokinetic (PK) and preliminary efficacy study of single agent NST-628 in adult patients with MAPK pathway mutated/dependent advanced solid …
Westwood, California and other locations
RSC-1255 for Treatment of Patients With Advanced Malignancies
open to eligible people ages 18 years and up
RSC-101 is a Phase 1a/1b clinical trial of RSC-1255 in adult study participants with advanced solid tumor malignancies who are intolerant of existing therapies known to provide clinical benefit, have disease that has progressed after standard…
Los Angeles, California and other locations
Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers
open to eligible people ages 18 years and up
This study is researching an investigational drug called REGN7075 by itself and in combination with cemiplimab with or without chemotherapy. The study is focused on patients with certain solid tumors that are in an advanced stage. The aim of the…
Los Angeles, California and other locations
Extension Study for Patients Previously Enrolled in Studies with Pelabresib
open to eligible people ages 18 years and up
The purpose of this study is: 1. To provide continued pelabresib treatment to patients who have previously received pelabresib in a parent study and continue collecting safety and efficacy information 2. To evaluate the overall survival and…
Los Angeles, California and other locations
Expansion of BBO-10203 in Advanced Solid Tumors (BREAKER-101)
open to eligible people ages 18 years and up
First in human study to evaluate the safety, tolerability, and pharmacokinetics (PK) of BBO-10203, a PI3Kα:RAS breaker, alone and in combination with trastuzumab in patients with advanced solid tumors.
Los Angeles, California and other locations
RBS2418 in Subjects With Advanced, Metastatic Solid Tumors
open to eligible people ages 18 years and up
RBS2418 (investigational product) is a specific immune modulator, working through ectonucleotide pyrophosphatase/phosphodiesterase I (ENPP1), designed to lead to anti-tumor immunity by increasing endogenous 2'-3'-cyclic guanosine…
Santa Monica, California and other locations
First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer
open to eligible people ages 18 years and up
This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-2-307-ADC in patients with advanced cancer
Los Angeles, California and other locations
First in Human Study of TORL-3-600 in Participants With Advanced Cancer
open to eligible people ages 18 years and up
This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-3-600 in patients with advanced cancer
Los Angeles, California and other locations
First in Human Study of UCT-03-008 in Participants With Advanced Solid Tumors
open to eligible people ages 18 years and up
This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of UCT-03-008 in patients with advanced solid tumors.
Los Angeles, California and other locations
First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors
open to eligible people ages 18 years and up
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1305/BNT325 in subjects with advanced solid tumors.
Los Angeles, California and other locations
First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer
open to eligible people ages 18 years and up
OKI-219-101 is a Phase 1a/1b, open-label, multicenter, dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and efficacy of OKI-219 as monotherapy and in combination with fulvestrant or…
Los Angeles, California and other locations
Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
open to eligible people ages 18-75
This phase I trial studies the side effects and best dose of modified immune cells (IL13Ralpha2 CAR T cells) after a chemotherapy conditioning regimen for the treatment of patients with stage IIIC or IV melanoma or solid tumors that have spread to…
Los Angeles, California and other locations
PK of Olaparib in Paediatric Patients With Solid Tumours
open to eligible people ages 0-18
A study to find out whether olaparib is safe and well tolerated when administered to children and adolescents with solid tumours.
Los Angeles, California and other locations
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
open to eligible people ages 18 years and up
This first-in-human (FIH) dose-escalation and dose-validation/expansion study will assess KO-2806, a farnesyl transferase inhibitor (FTI), as a monotherapy and in combination, in adult patients with advanced solid tumors.
Los Angeles, California and other locations
Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
open to eligible people ages 18 years and up
The purpose of this study is to evaluate the long-term safety and efficacy of pembrolizumab (MK-3475) in participants from previous Merck pembrolizumab-based parent studies who transition into this extension study. This study will consist of three…
Los Angeles, California and other locations
MOONRAY-01, a Study of LY3962673 in Participants with KRAS G12D-Mutant Solid Tumors
open to eligible people ages 18 years and up
The main purpose of this study is to assess safety & tolerability and antitumor activity of LY3962673 as monotherapy and in combination with other chemotherapy agents in participants with KRAS G12D-mutant advanced solid tumor types. The study is…
Los Angeles, California and other locations
Expansion to Assess the Safety, Tolerability, and PK of TRE-515 in Subjects With Solid Tumors
open to eligible people ages 18 years and up
TRE-515 is a first-in-class small molecule inhibitor of deoxycytidine kinase (dCK) that is being developed for oral administration in patients with solid tumors. In cancer cells, rapid and upregulated DNA replication creates high replication stress, …
Santa Monica, California and other locations
Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor
open to eligible people ages 18 years and up
This study is open to adult patients with solid tumors who have a KRAS G12V mutation. This mutation is often found in non-small cell lung cancer (NSCLC), colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC) and other cancers. The study…
Los Angeles, California and other locations
PRT3789 Monotherapy and in Combo w/Docetaxel in Participants w/Advanced or Metastatic Solid Tumors w/SMARCA4 Mutation
open to eligible people ages 18 years and up
This is a Phase 1 dose-escalation study of PRT3789, a SMARCA2 degrader, in participants with advanced or metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The purpose of this study is to evaluate the safety,…
Santa Monica, California and other locations
Rinatabart Sesutecan (Rina-S) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
open to eligible people ages 18 years and up
This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot…
Los Angeles, California and other locations
STK-012 Monotherapy and in Combination Therapy in Patients with Solid Tumors
open to eligible people ages 18 years and up
This is a first-in-human, phase 1a/1b, multicenter, open-label, dose escalation study of STK-012 as monotherapy and in combination therapy in patients with selected advanced solid tumors.
Santa Monica, California and other locations
CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation
open to eligible people ages 18 years and up
This is an open-label, multi-center, phase 1b study designed to determine a tolerable dose of CX-5461 administered by IV infusion on Day 1 and Day 8 of a 28-day cycle in patients with selected solid tumours and associated mutations for future Phase…
Santa Monica, California and other locations
Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
open to eligible people ages 18-130
TROPION-PanTumor03 will investigate the safety, tolerability, and anti-tumour activity of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination with Anticancer Agents in Patients with Advanced/Metastatic Solid Tumours.
Los Angeles, California and other locations
HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.
open to eligible people ages 18-100
The main purpose of the study is to evaluate the safety and tolerability of HRO761 and identify the recommended dose(s), i.e., the optimal safe and active dose of HRO761 alone or in combination with pembrolizumab or irinotecan that can be given to…
Los Angeles, California and other locations
IDE196 in Patients with Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
open to eligible people ages 18 years and up
This is a Phase 1/2, multi-center, open-label basket study designed to evaluate the safety and anti-tumor activity of IDE196 in patients with solid tumors harboring GNAQ or GNA11 (GNAQ/11) mutations or PRKC fusions, including metastatic uveal…
Los Angeles, California and other locations
RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
open to eligible people ages 18 years and up
The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors combined with Standard(s) of Care (SOC) or with novel agents. The current subprotocols…
Los Angeles, California and other locations
RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
open to eligible people ages 18 years and up
Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors.
Santa Monica, California and other locations
RP1 Monotherapy and RP1 in Combination With Nivolumab
open to eligible people ages 18 years and up
RPL-001-16 is a Phase 1/2, open label, dose escalation and expansion clinical study of RP1 alone and in combination with nivolumab in adult subjects with advanced and/or refractory solid tumors, to determine the maximum tolerated dose (MTD) and…
Los Angeles, California and other locations
BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
open to eligible people ages 18 years and up
The investigational drug to be studied in this protocol, BCA101, is a first-in-class compound that targets both EGFR with TGFβ. Based on preclinical data, this bifunctional antibody may exert synergistic activity in patients with EGFR-driven tumors.
Los Angeles, California and other locations
CHK1 Inhibitor BBI-355, an EcDNA-directed Therapy (ecDTx), in Subjects with Tumors with Oncogene Amplifications
open to eligible people ages 18 years and up
BBI-355 is an oral, potent, selective checkpoint kinase 1 (or CHK1) small molecule inhibitor in development as an ecDNA (extrachromosomal DNA) directed therapy (ecDTx). This is a first-in-human, open-label, 3-part, Phase 1/2 study to determine the…
Los Angeles, California and other locations
TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors
open to eligible people ages 18 years and up
The goal of this interventional clinical trial is to learn about TNG260, a CoREST inhibitor, in combination with pembrolizumab in patients with advanced solid tumors with a known STK11 mutation. The main question[s] it aims to answer are: - the…
Santa Monica, California and other locations
BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
open to eligible people ages 18 years and up
The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-B01D1 in patients with Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors.
Duarte, California and other locations
SW-682 in Advanced Solid Tumors
open to eligible people ages 18 years and up
This is a first-in-human (FIH), Phase 1a/1b open-label, multicenter, dose escalation and dose expansion study of SW-682 in adult participants with metastatic or unresectable advanced solid tumors with or without Hippo pathway alterations that are…
Los Angeles, California and other locations
HistoSonics Edison™ System for Treatment of Primary Solid Renal Tumors Using Histotripsy (#HOPE4KIDNEY)
open to eligible people ages 22 years and up
The purpose of this trial is to evaluate the effectiveness and safety of the HistoSonics Edison System for the destruction of kidney tissue by treating primary solid renal tumors.
Los Angeles, California and other locations
ABL503, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL503 in Subjects with Any Progressive Locally Advanced or Metastatic Solid Tumors
open to eligible people ages 18 years and up
This is a first-in-human Phase 1, single-arm, open-label, multicenter, multiple-dose, dose-escalation and dose-expansion study of ABL503 to evaluate the safety, tolerability, MTD and/or RP2D, PK, immunogenicity, preliminary antitumor activity, and…
Santa Monica, California and other locations
DFP-14927 in Advanced Solid Tumors
open to eligible people ages 18 years and up
This is a Phase I, open-label, single-arm, dose escalation study of DFP-14927 intravenous infusion administered to patients with refractory or relapsed solid tumors.
Los Angeles, California and other locations
Vilastobart (XTX101) Monotherapy and Vilastobart and Atezolizumab Combination Therapy in Advanced Solid Tumors
open to eligible people ages 18 years and up
This is a first-in-human, Phase 1/2, multicenter, open-label study designed to evaluate the safety and tolerability of vilastobart (XTX101) as monotherapy and vilastobart (XTX101) and atezolizumab combination therapy in patients with advanced solid…
Santa Monica, California and other locations
Patients Who Have Participated in Children's Oncology Group Studies
open to all eligible people
This clinical trial keeps track of and collects follow-up information from patients who are currently enrolled on or have participated in a Children's Oncology Group study. Developing a way to keep track of patients who have participated in…
Los Angeles, California and other locations
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
open to eligible people ages 18 years and up
Objective: To collect information on how often a solid tumor cancer might lose the Human Leukocyte Antigen (HLA) by next generation sequencing and perform apheresis to collect and store an eligible participant's own T cells for future use to make…
Santa Monica, California and other locations
Learn More About the Safety and Effectiveness of the Drug VITRAKVI During Routine Use in Patients With TRK Fusion Cancer Which is Locally Advanced or Spread From the Place Where it Started to Other Places in the Body
open to all eligible people
In this observational study researcher want to learn more about the effectiveness of drug VITRAKVI (generic name: larotrectinib) and how well the drug is tolerated during routine use in patients with TRK fusion cancer which is locally advanced or…
Los Angeles, California and other locations
SHP2 Inhibitor in Patients With Solid Tumors Harboring KRAS of EGFR Mutations
open to eligible people ages 18 years and up
A Phase 1 dose escalation study in patients with advanced solid tumors harboring KRAS or EGFR mutations to determine the maximum tolerated dose and recommended Phase II dose of HBI-2376 and characterize its pharmacokinetic profile.
Santa Monica, California and other locations
EP0031 in Patients With Advanced RET-altered Malignancies
open to eligible people ages 18 years and up
The aim of this study is to assess the safety, side effects and effectiveness of EP0031 in patients with advanced RET-altered malignancies
Los Angeles, California and other locations
PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors
open to eligible people ages 18 years and up
This study will test the safety of a drug called PF-08046049/SGN-BB228 in participants with melanoma and other solid tumors that are hard to treat or have spread through the body. It will also study the side effects of this drug. A side effect is…
Los Angeles, California and other locations
A2B530, a Logic-gated CAR T, in Participants with Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression
open to eligible people ages 18 years and up
The goal of this study is to test A2B530,an autologous logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorectal cancer (CRC), pancreatic cancer (PANC), non-small cell lung cancer (NSCLC), and other solid tumors that…
Los Angeles, California and other locations
A2B694, a Logic-gated CAR T, in Participants with Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
open to eligible people ages 18 years and up
The goal of this study is to test A2B694, an autologous logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorectal cancer (CRC), pancreatic cancer (PANC), non-small cell lung cancer (NSCLC), ovarian cancer (OVCA),…
Los Angeles, California and other locations
BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours
open to eligible people ages 18 years and up
BOLD-100 is an intravenously administered sterile solution containing the ruthenium-based small molecule. BOLD-100 has been shown to preferentially decrease the expression of GRP78 in tumour cells and ER stressed cells when compared to normal cells. …
Santa Monica, California and other locations
First in Human Study of TORL-1-23 in Participants with Advanced Cancer
open to eligible people ages 18 years and up
This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-1-23 in patients with advanced cancer
Los Angeles, California and other locations
Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies
open to eligible people ages 18 years and up
The primary objective is to assess the safety and tolerability of TAB004 as monotherapy and in combination with toripalimab in subjects with selected advanced solid malignancies, including lymphoma, and to evaluate the recommended Phase 2 dose. The…
Los Angeles, California and other locations
Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
open to eligible people ages 18-100
To evaluate the safety and tolerability of sotorasib administered in investigational regimens in adult participants with KRAS p.G12C mutant advanced solid tumors.
Santa Monica, California and other locations
AMG 193 in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors
Sorry, in progress, not accepting new patients
The main aims of this study are to evaluate the safety and tolerability, and to determine the maximum tolerated dose (MTD) or the recommended combination dose of AMG 193 in combination with IDE397 in adult participants with metastatic or locally…
Duarte, California and other locations
LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment
Sorry, in progress, not accepting new patients
The main purpose of this study is to learn more about the safety, side effects, and effectiveness of LOXO-260. LOXO-260 may be used to treat cancer that has a change in a particular gene (known as the RET gene). Participation could last up to 24…
Los Angeles, California and other locations
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
Sorry, in progress, not accepting new patients
This Master Protocol for Avelumab Continuation Sub-Studies is to provide continued treatment access, safety follow-up, and when applicable, overall survival follow-up for eligible participants who continue to derive a benefit from study intervention …
Los Angeles, California and other locations
Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.
Sorry, accepting new patients by invitation only
Multicenter, open-label, prospective treatment protocol that provides continued access to ibrutinib to subjects who have completed parent ibrutinib studies, are still benefitting from treatment with ibrutinib, and have no access to commercial…
Los Angeles, California and other locations
First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)
Sorry, in progress, not accepting new patients
This study is one single group of participants with non-small cell lung cancer (NSCLC) who have not been cured by other treatments. It is the first time the drug has been used in humans. There will be two parts and a sub-study. The primary purpose…
Los Angeles, California and other locations
Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies
Sorry, not currently recruiting here
A Phase I-II, First-in-Human Study of SKB264 in Patients with Locally Advanced Unresectable/Metastatic Solid Tumors who are refractory to Available Standard Therapies. Patient must have historically documented, incurable, locally advanced or…
Los Angeles, California and other locations
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
Sorry, in progress, not accepting new patients
This Pediatric MATCH screening and multi-sub-study phase II trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed…
Los Angeles, California and other locations
[225Ac]-FPI-2068 in Adult Patients with Advanced Solid Tumours
Sorry, not currently recruiting here
This is a first-in-human, Phase 1, non-randomized, multicenter, open-label clinical study designed to investigate the safety, tolerability, dosimetry, biodistribution, and pharmacokinetics (PK) of [225Ac]-FPI-2068, [111In]-FPI-2107, and FPI-2053 in…
Santa Monica, California and other locations
PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)
Sorry, in progress, not accepting new patients
Evaluate the safety and tolerability of sotorasib in adult subjects with KRAS p.G12C mutant advanced solid tumors. Estimate the maximum tolerated dose (MTD) and/or a recommended phase 2 dose (RP2D) in adult subjects with KRAS p.G12C mutant advanced…
Los Angeles, California and other locations
AZD0022 as Monotherapy and in Combination With Anti-cancer Agents in Adult Participants With Tumours Harbouring a KRASG12D Mutation
Sorry, not currently recruiting here
This is a first-in-human, modular, Phase I/IIa, open-label, multi-centre study to assess the safety, tolerability, PK, and preliminary efficacy of AZD0022 monotherapy in combination with other anti-cancer agents in participants with tumours…
Los Angeles, California and other locations
ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
Sorry, in progress, not accepting new patients
This study employs a 2-stage design that aims to evaluate the efficacy and safety of ENV- 101, a potent Hedgehog (Hh) pathway inhibitor, in patients with refractory advanced solid tumors characterized by loss of function (LOF) mutations in the…
Los Angeles, California and other locations
(PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors
Sorry, in progress, not accepting new patients
This is a Phase 1/1b open-label study evaluating the safety, pharmacokinetics (PK), and preliminary efficacy of ABBV-399 as monotherapy and in combination with osimertinib, erlotinib, and nivolumab in participants with advanced solid tumors likely…
Los Angeles, California and other locations
Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma
Sorry, in progress, not accepting new patients
The study's purpose is to see if the drug, abemaciclib, is safe and effective when given with other drugs to kill cancer cells. The study is open to children and young adults with solid tumors, including neuroblastoma, that did not respond or grew…
Los Angeles, California and other locations
Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors
Sorry, in progress, not accepting new patients
The main aim of this study is to check if people with advanced solid tumors have side effects from dazostinag, and to check how much dazostinag they can receive without getting significant side effects from it when given alone and in combination…
Santa Monica, California and other locations
E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor
Sorry, not currently recruiting here
The primary objective of this study is to assess the safety and tolerability and to determine the recommended Phase 2 dose (RP2D) of E7386 in combination with other anticancer drug(s), and to determine the optimal dose of E7386 in combination with…
Santa Monica, California and other locations
ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors
Sorry, in progress, not accepting new patients
This is a Phase 1/2 study to assess the safety and efficacy of ELI-002 7P immunotherapy (a lipid-conjugated immune-stimulatory oligonucleotide [Amph-CpG-7909] plus a mixture of lipid-conjugated peptide-based antigens [Amph-Peptides 7P]) as adjuvant…
Los Angeles, California and other locations
ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors
Sorry, in progress, not accepting new patients
This is a Phase 1 study to assess the safety and efficacy of ELI-002 immunotherapy (a lipid-conjugated immune-stimulatory oligonucleotide [Amph-CpG-7909] plus a mixture of lipid-conjugated peptide-based antigens [Amph-Peptides]) as adjuvant…
Los Angeles, California and other locations
Lorigerlimab in Participants With Advanced Solid Tumors
Sorry, not yet accepting patients
Study CP-MGD019-03 is an open-label study of lorigerlimab in participants with platinum-resistant ovarian cancer (PROC) or clear cell gynecologic cancer (CCGC). Approximately 60 participants will be enrolled. The study will assess the efficacy and…
Los Angeles, California and other locations
LOXO-783 in Patients With Breast Cancer/Other Solid Tumors
Sorry, in progress, not accepting new patients
The main purpose of this study is to learn more about the safety, side effects, and effectiveness of LOXO-783. LOXO-783 may be used to treat breast cancer and other solid tumors that have a change in a particular gene (known as the PIK3CA gene).…
Santa Monica, California and other locations
LY4050784 in Participants With Advanced or Metastatic Solid Tumors
Sorry, not currently recruiting here
The main purpose of this study is to find out whether the study drug, LY4050784, is safe, tolerable and effective in participants with locally advanced or metastatic solid tumors with a BRG1 (Brahma-related gene 1, also known as SMARCA4) alteration…
Santa Monica, California and other locations
MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors
Sorry, in progress, not accepting new patients
Study CP-MGC018-02 is a study of vobramitamab duocarmazine (MGC018) in combination with lorigerlimab (MGD019). The study is designed to characterize safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics, and preliminary…
Los Angeles, California and other locations
Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)
Sorry, in progress, not accepting new patients
This is an open-label, first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of selpercatinib (also known as LOXO-292) administered orally to participants with advanced solid…
Los Angeles, California and other locations
Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Sorry, not currently recruiting here
The main purpose of the study is to assess whether the study drug, LY4066434, is safe and tolerable when administered to participants with locally advanced or metastatic solid tumors with certain KRAS mutations. LY4066434 will be given alone or in…
Los Angeles, California and other locations
XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors
Sorry, in progress, not accepting new patients
This is a Phase 1, open-label, dose-escalation and expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect on biomarkers of XL092 administered alone, in combination with atezolizumab,…
Los Angeles, California and other locations
AB308 in Combination With AB122 in Participants With Advanced Malignancies
Sorry, in progress, not accepting new patients
This is a Phase 1/1b, multicenter, open-label, dose-escalation, and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and clinical activity of AB308 in combination with zimberelimab (AB122) in…
Los Angeles, California and other locations
Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor
Sorry, currently not accepting new patients, but might later
This is an open-label, Phase 1b/2 study to determine the recommended dose of lucitanib in combination with nivolumab in patients with an advanced solid tumor (Phase 1b); followed by evaluation of the safety and efficacy of lucitanib and nivolumab in …
Los Angeles, California and other locations
A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
Sorry, not currently recruiting here
The goal of this study is to test A2B395, an allogeneic logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorectal cancer (CRC), non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC),…
Los Angeles, California and other locations
Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-Care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors
Sorry, in progress, not accepting new patients
The purpose of this study is to evaluate the safety and tolerability of RO7496353 when administered in combination with a checkpoint inhibitor (CPI) with or without standard-of-care (SOC) chemotherapy in participants with locally advanced or…
Los Angeles, California and other locations
LYL797 in Adults With Solid Tumors
Sorry, in progress, not accepting new patients
This study will evaluate the safety and tolerability of LYL797, a ROR1-targeted CAR T-cell therapy, in patients with ROR1+ relapsed or refractory triple negative breast cancer (TNBC), non-small cell lung cancer (NSCLC), platinum-resistant epithelial …
Santa Monica, California and other locations
LYL845 in Adults With Solid Tumors
Sorry, in progress, not accepting new patients
This is an open-label, multi-center, dose-escalation study with expansion cohorts, designed to evaluate the safety and anti-tumor activity of LYL845, an epigenetically reprogrammed tumor infiltrating lymphocyte (TIL) therapy, in participants with…
Santa Monica, California and other locations
Intravenous QEQ278 in Patients With Advanced Solid Tumors
Sorry, in progress, not accepting new patients
To characterize safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of QEQ278 in adult patients with advanced/metastatic non-small cell lung cancer, esophageal squamous cell carcinoma, renal cell carcinoma,…
Los Angeles, California and other locations
Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors
Sorry, in progress, not accepting new patients
The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07220060 and PF-07104091) in people with breast cancer. This clinical study consists of 2 parts (part 1 and part 2). In part 1, we are…
Los Angeles, California and other locations
Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors
Sorry, in progress, not accepting new patients
This research study is done to test how well different types of cancer respond to the drug called larotrectinib. The cancer must have a change in a particular gene (NTRK1, NTRK2 or NTRK3). Larotrectinib is a drug that blocks the actions of these…
Santa Monica, California and other locations
Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children
Sorry, in progress, not accepting new patients
The study is being done to test the safety of a cancer drug called larotrectinib in children. The cancer must have a change in a particular gene (NTRK1, NTRK2 or NTRK3). Larotrectinib blocks the actions of these NTRK genes in cancer cells and can…
Los Angeles, California and other locations
Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2)
Sorry, in progress, not accepting new patients
This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 in combination with TNO155 in patients with advanced solid tumors that have a KRAS G12C mutation.
Los Angeles, California and other locations
Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations
Sorry, not currently recruiting here
This is a study for people with advanced cancer for whom previous treatment was not successful. Adults aged 18 and over with advanced cancer with HER2 alterations can join the study. The purpose of this study is to find out whether a medicine called …
Los Angeles, California and other locations
Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors
Sorry, in progress, not accepting new patients
This is a Phase 1, multicenter, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and preliminary evidence of antitumor activity of CPO-100 administered intravenously in cycles of 3 weekly…
Los Angeles, California and other locations
First in Human Study of TORL-2-307-MAB in Participants With Advanced Cancer
Sorry, in progress, not accepting new patients
This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-2-307-MAB in patients with advanced cancer
Los Angeles, California and other locations
GEN1047 for Solid Tumors - First in Human (FIH) Trial
Sorry, in progress, not accepting new patients
The purpose of this trial is to measure the following in participants with solid tumors who receive GEN1047: - The side effects seen with GEN1047 - What the body does with GEN1047 once it is administered - What GEN1047 does to the body once it is…
Los Angeles, California and other locations
Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)
Sorry, in progress, not accepting new patients
This phase II Pediatric MATCH trial studies how well ivosidenib works in treating patients with solid tumors that have spread to other places in the body (advanced), lymphoma, or histiocytic disorders that have IDH1 genetic alterations (mutations).…
Los Angeles, California and other locations
KZR-261 in Subjects With Advanced Solid Malignancies
Sorry, in progress, not accepting new patients
A first-in-human, open-label, multicenter, Phase 1 study of KZR-261 designed to assess the safety and tolerability, preliminary anti-tumor activity, and pharmacokinetics (PK) of KZR-261, as well as identify the recommended Phase 2 dose (RP2D). The…
Los Angeles, California and other locations
Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy
Sorry, currently not accepting new patients, but might later
This phase Ib/II trial studies the best dose of temozolomide and how well it works with niraparib and atezolizumab in treating patients with solid tumors that have spread to other places in the body (advanced) and extensive-stage small cell lung…
Los Angeles, California
First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors
Sorry, in progress, not accepting new patients
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of intravenous (IV) administration of XmAb808 in combination with pembrolizumab in subjects with selected advanced solid tumors and to identify the minimum safe…
Los Angeles, California and other locations
Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)
Sorry, in progress, not accepting new patients
A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes
Los Angeles, California and other locations
Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors
Sorry, in progress, not accepting new patients
This is a nonrandomized, uncontrolled, open-label, multicenter Phase 2 study to evaluate the efficacy, safety, and tolerability of futibatinib in combination with PD-1 antibody-based SoC therapy in adult patients with solid tumors.
Santa Monica, California and other locations
TNG908 in Patients With MTAP-deleted Solid Tumors
Sorry, in progress, not accepting new patients
This is a first in human study in patients with advanced or metastatic solid tumors known to have an MTAP deletion. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific…
Los Angeles, California and other locations
Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial
Sorry, in progress, not accepting new patients
This phase II pediatric MATCH treatment trial studies how well selpercatinib works in treating patients with solid tumors that may have spread from where they first started to nearby tissue, lymph nodes, or distant parts of the body (advanced),…
Los Angeles, California and other locations
ART0380 in Patients With Biologically Selected Solid Tumors
Sorry, in progress, not accepting new patients
This interventional study will evaluate the efficacy and safety of ART0380 as monotherapy in patients whose tumors have a biology to predict for sensitivity to inhibition of Ataxia-Telangiectasia Mutated and Rad3-related protein kinase (ATR).
Los Angeles, California and other locations
Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors
Sorry, not currently recruiting here
A prospective, open-label, multi-cohort, non-randomized, multicenter Phase 2 study evaluating adoptive cell therapy (ACT) with TIL LN-144 (Lifileucel)/LN-145 in combination with checkpoint inhibitors or TIL LN-144 (Lifileucel)/LN-145/LN-145-S1 as a…
Los Angeles, California and other locations
ORM-5029 in Subjects with HER2-Expressing Advanced Solid Tumors
Sorry, in progress, not accepting new patients
This is a Phase 1 first-in-human study of ORM-5029 in participants with HER2-expressing advanced solid tumors. The study consists of two parts: a Part 1 Dose Escalation and Part 2 Dose Expansion.
Los Angeles, California and other locations
RP-6306 Alone or in Combination with RP-3500 or Debio 0123 in Patients with Advanced Solid Tumors
Sorry, not currently recruiting here
The primary purpose of this study is to assess the safety and tolerability of RP-6306 alone and in combination with RP-3500 or in combination with Debio 0123 in patients with eligible advanced solid tumors, determine the maximum tolerated dose (MTD) …
Los Angeles, California and other locations
RP-6306 with FOLFIRI in Advanced Solid Tumors
Sorry, in progress, not accepting new patients
The primary purpose of this study is to assess the safety and tolerability of RP-6306 with FOLFIRI in patients with eligible advanced solid tumors, determine the maximum tolerated dose (MTD), identify a recommended phase 2 dose (RP2D) and preferred…
Los Angeles, California and other locations
RP-6306 With Gemcitabine in Advanced Solid Tumors
Sorry, in progress, not accepting new patients
The primary purpose of this study is to assess the safety and tolerability of RP-6306 in combination gemcitabine, in patients with eligible advanced solid tumors, determine the maximum tolerated dose (MTD) of RP-6306 in combination with gemcitabine, …
Los Angeles, California and other locations
Sacituzumab Govitecan in Participants With Metastatic Solid Tumors
Sorry, in progress, not accepting new patients
The goal of this clinical study is to learn more about the study drug, sacituzumab govitecan-hziy, in participants with metastatic (cancer that has spread) solid tumors.
Los Angeles, California and other locations
Pre-surgical Aerobic Exercise on Patients With Solid Tumors
Sorry, in progress, not accepting new patients
The purpose of this study is to find the safest level of aerobic training for people about to undergo surgery for their cancer, and to learn what effects, if any, aerobic exercise has on these patients and the outcomes of their cancers. This part of …
Los Angeles, California and other locations
BGB-283 (Lifirafenib) and PD-0325901 (Mirdametinib) in Participants With Advanced or Refractory Solid Tumors
Sorry, in progress, not accepting new patients
This is a 2-part Phase 1b study of BGB-283 (lifirafenib) and PD-0325901 (mirdametinib) combination in participants with tumors.
Santa Monica, California and other locations
Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab
Sorry, in progress, not accepting new patients
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events and change in disease activity when ABBV-400 is given to adult participants to treat advanced solid …
Los Angeles, California and other locations
PC14586 in Patients with Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Sorry, not currently recruiting here
The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1…
Los Angeles, California and other locations
Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial
Sorry, in progress, not accepting new patients
This phase II pediatric MATCH trial studies how well tipifarnib works in treating patients with solid tumors that have recurred or spread to other places in the body (advanced), lymphoma, or histiocytic disorders, that have a genetic alteration in…
Los Angeles, California and other locations
Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
Sorry, in progress, not accepting new patients
This phase II Pediatric MATCH trial studies how well ulixertinib works in treating patients with solid tumors that have spread to other places in the body (advanced), non-Hodgkin lymphoma, or histiocytic disorders that have a genetic alteration…
Los Angeles, California and other locations
XTX202 in Patients With Advanced Solid Tumors
Sorry, in progress, not accepting new patients
A First-in-Human, Multicenter, Phase 1/2, Open-Label Study of XTX202 in Patients with Advanced Solid Tumors
Los Angeles, California and other locations
Treatment of Cancers With Rearranged During Transfection (RET) Activation
Sorry, not accepting new patients
Expanded access for participants with cancer with RET activation who are ineligible for an ongoing selpercatinib (also known as LOXO-292) clinical trial or have other considerations that prevent access to selpercatinib through an existing clinical…
Los Angeles, California and other locations
Our lead scientists for Solid Tumor research studies include Marla D. Lipsyc-Sharf, MD Gary J. Schiller, MD Wanxing Chai-Ho, MD Nicholas P. McAndrew, MD, MSCE Alexandra Drakaki, MD Noah C. Federman, MD Edward B. Garon, MD, MS Antoni Ribas, MD Gottfried E. Konecny, MD J. Randolph Hecht, MD Sven de Vos, MD, PhD Bartosz Chmielowski, MD, PhD Zev A. Wainberg, MD Deborah J. Wong, MD, PhD Aaron Lisberg, MD Jonathan Goldman, MD Arun S. Singh, MD Edward Garon Brian M. Shuch, MD Lee S. Rosen, MD Salani Ritu, MD Satiro De Oliveira, MD.
Last updated: